Efficacy of anti-osteoporosis drugs in patients with hip fracture

Efficacy of anti-osteoporosis drugs in patients with hip fracture The most compelling evidence to support anti-osteoporosis treatment in hip fracture patients comes from zoledronic acid, a bisphosphonate. The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly

(HORIZON) Recurrent Fracture Selonsertib ic50 Trial (RFT) was a secondary prevention study that involved 1,065 subjects (75% women) with mean age 75 ± 9 years and incidental hip fracture. Zoledronic acid at a dose of 5 mg administered as a yearly 15-minute intravenous infusion with the first dose being given within 90 days after hip fracture Selleckchem LCZ696 surgery significantly reduced any new clinical fracture by 35%, clinical vertebral fracture by 46% and non-vertebral fracture by 27% after a mean follow-up of 1.9 years. Risk of hip fracture was reduced by 30% but this was not significant

due to the low number of events [60]. There was also a significant 28% reduction in all-cause mortality in the active treatment group [60]. Though the exact underlying mechanism responsible for this improved survival has yet to be elucidated, an exploratory analysis showed that zoledronic acid-treated subjects were less likely to die from pneumonia and arrhythmias than placebo-treated subjects [61]. A pivotal study of Zoledronic acid, the HORIZON Pivotal buy GDC-0941 Fracture Trial, that involved 3,889 postmenopausal osteoporotic women with a mean age of 73 ± 5 years (38% were >75 years of age) also showed a significant 70% reduction in the Branched chain aminotransferase incidence of morphometric vertebral fracture, a 25% reduction in non-vertebral fracture, and a 41% reduction in hip fracture at 36 months [62]. Subgroup analysis in subjects aged ≥75 years was not available. Significant anti-fracture efficacy at the spine in the elderly population was also evident for two other bisphosphonates, alendronate, and risedronate. Pooled analysis of the combined data of 1,392 women ≥80 years of age (mean age 83 ± 3 years) from the three major phase three clinical trials of risedronate showed that risedronate

5 mg daily significantly reduced the risk of new vertebral fracture by 81% at 1 year and 44% at 3 years. The NNT were 12 and 16 after 1 and 3 years, respectively. The reduction in risk of non-vertebral fracture was nonetheless not significant at either time point [63]. In a subgroup analysis of 539 women aged ≥75 years (range 75–82 years) in the Fracture Intervention Trial, alendronate significantly reduced new vertebral fracture by 38% at 3 years. The corresponding NNT was 13. Data on non-vertebral fracture reduction were unavailable [64]. Agents with bone-forming properties, teriparatide and strontium ranelate, have also shown evidence of fracture risk reduction in older patients.

Comments are closed.